ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston.

As part of her presentation on ‘Enhancing persistence and efficacy of CAR-T therapies’ at the US conference last week, Senior VP of Scientific Affairs Dr Rebecca Lim revealed Prescient’s eagerly anticipated novel adjuvant/neoadjuvant, CellPryme-A.

The adjuvant therapy – which has been shown to boost the effectiveness and proliferation of CAR-T therapies, significantly improving tumour killing and survival – represents a leap forward for Prescient (ASX: PTX) in its mission to move cancer care from treatments towards personalised cures.

It is designed to be administered to cancer patients as an intravenous infusion to boost the effectiveness of cellular immunotherapy, such as CAR-T cell therapy, by overcoming the hostile tumour microenvironment that acts as a ‘force field’ for solid tumours.

CellPryme-A enhances tumour killing of conventional CAR-T cells and improves host survival by reducing suppressive Treg cells, increasing infiltration of CAR-T cells into solid tumours and dramatically increasing the ability of CAR-T cells to expand in vivo, the company said.

CEO and MD Steven Yatomi-Clarke said he was delighted that CellPryme-A – developed in collaboration with the Peter MacCallum Cancer Centre – expanded Prescient’s stable of cell therapy enhancements, noting it was “a distinct but complementary addition” to CellPryme-M.

Both platforms are also complementary with Prescient’s flagship OmniCAR platform, and can be incorporated into existing cell therapy programs as they enter clinical studies, opening up avenues for external collaborations and in-house applications, Mr Yatomi-Clarke said.

“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” he said.

“These industry challenges – which include targeting an array of antigens, post infusion control, cell exhaustion and a suppressive tumour microenvironment – simply must be overcome in order to bring this promising new class of therapies to more patients, and to conquer different malignancies.

“We now have a comprehensive suite of technologies to address all of these challenges.”

Prescient Therapeutics CEO and MD Steven Yatomi-Clarke will be holding an investor briefing on Friday, 30th September, at 1pm (AEST) where he will provide an overview of the company’s deep pipeline. Click here to book in.

Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.

Past performance is not a reliable indicator of future performance.

Sources:

• PTX ASX Announcement, Prescient Unveils CellPryme-A: Novel Adjuvant for Enhancing Cellular Immunotherapy